@Buson2 ayrıca bu makale Johns Hopkins Tıp Fakültesi, Enfeksiyon Hastalıkları Bölümü, Baltimore, Maryland, ABD'nin 8 doktorunun (Spivak, Adam M; Sydnor, Emily RM; Blankson, Joel N; Gallant, Joel E) makalesi. Git iyi araştır böyle cahil cahil de ortalarda gezme.
@Buson2 Salak mısın sen? İngilizcem iyi diye buradaki 57 kaynağın hepsini ezbere yazmam mı gerekiyor buraya? Bu kafayı bulmak için sen birşey mi içiyorsun?
@pişmanpasif aynen o lenflerle ben de ne yapacağımı bilmiyorum. Doktor sulu-alkollu bez koy üzerine günde 4 saat dedi ama 3 gündür yapıyorum yine bir sonuç yok. Aynı yerinde duruyor.
@Buson2 Bu adam yazmış. Zaten makaledede en üstte ''author information'' kısmında yazıyor (Johns Hopkins School of Medicine, Division of Infectious Diseases, Baltimore, Maryland, USA.) ama o da kendi kafasında uydurmamış alttaki kaynakları derlemiş. Yani bunları: References 1. United States Food and Drug Administration. HIV/AIDS historical time line 1981–1990. http://www.fda.gov/oashi/aids/miles81.html; 2009. [Accessed 17 March 2009] 2. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). 2009 AIDS epidemic update [UNAIDS/09.36E/JC1700E, English original]. www.unaids.org; November 2009. 3. van Binsbergen J, Siebelink A, Jacobs A, Keur W, Bruynis F, van de Graaf M, et al. Improved performance of seroconversion with a 4th generation HIV antigen/antibody assay. J Virol Methods 1999; 82:77–84. 4. World Health Organization. Guidance on provider-initiated HIV testing and counselling in health facilities.www.unaids.org; 2007. 5. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55:1–17, quiz CE1–4. Cited Here 6. Gurtler L. Difficulties and strategies of HIV diagnosis. Lancet 1996; 348:176–179. Cited Here | View Full Text | PubMed | CrossRef 7. Sloand EM, Pitt E, Chiarello RJ, Nemo GJ. HIV testing. State of the art. JAMA 1991; 266:2861–2866. Cited Here | PubMed | CrossRef 8. Mylonakis E, Paliou M, Lally M, Flanigan TP, Rich JD. Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am J Med 2000; 109:568–576. Cited Here | View Full Text | PubMed | CrossRef 9. Kleinman S, Busch MP, Hall L, Thomson R, Glynn S, Gallahan D, et al. False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation. Retrovirus Epidemiology Donor Study. JAMA 1998; 280:1080–1085. Cited Here | View Full Text | PubMed | CrossRef 10. Owen SM, Yang C, Spira T, Ou CY, Pau CP, Parekh BS, et al. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol 2008; 46:1588–1595. Cited Here | PubMed | CrossRef 11. Burin des Roziers N, Sotto A, Arnaud A, Saissi G, Nasar O, Jourdan J. Kinetics of detection of antibodies to HIV-1 and plasma p24 antigens during a severe primary HIV-1 infection. AIDS 1995; 9:528–529. Cited Here | PubMed | CrossRef 12. Busch MP, Lee LL, Satten GA, Henrard DR, Farzadegan H, Nelson KE, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995; 35:91–97. Cited Here | PubMed | CrossRef 13. Zouhair S, Roussin-Bretagne S, Moreau A, Brunet S, Laperche S, Maniez M, et al. Group o human immunodeficiency virus type 1 infection that escaped detection in two immmunoassays. J Clin Microbiol 2006; 44:662–665. Cited Here | PubMed | CrossRef 14. Loussert-Ajaka I, Ly TD, Chaix ML, Ingrand D, Saragosti S, Courouce AM, et al. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet 1994; 343:1393–1394. Cited Here | View Full Text | PubMed | CrossRef 15. Markovitz DM. Infection with the human immunodeficiency virus type 2. Ann Intern Med 1993; 118:211–218. Cited Here | View Full Text | PubMed | CrossRef 16. Schable C, Zekeng L, Pau CP, Hu D, Kaptue L, Gurtler L, et al. Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections. Lancet 1994; 344:1333–1334. Cited Here | View Full Text | PubMed | CrossRef 17. Simon F, Mauclere P, Roques P, Loussert-Ajaka I, Muller-Trutwin MC, Saragosti S, et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 1998; 4:1032–1037. Cited Here | PubMed | CrossRef 18. Kassutto S, Johnston MN, Rosenberg ES. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 2005; 40:868–873. Cited Here | View Full Text | PubMed | CrossRef 19. Hare CB, Pappalardo BL, Busch MP, Karlsson AC, Phelps BH, Alexander SS, et al. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis 2006; 42:700–708. Cited Here | View Full Text | PubMed | CrossRef 20. Jurriaans S, Sankatsing SU, Prins JM, Schuitemaker H, Lange J, Van Der Kuyl AC, et al. HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil. AIDS 2004; 18:1607–1608. Cited Here | View Full Text | PubMed | CrossRef 21. Padeh YC, Rubinstein A, Shliozberg J. Common variable immunodeficiency and testing for HIV-1. N Engl J Med 2005; 353:1074–1075. Cited Here | View Full Text | PubMed | CrossRef 22. Soriano V, Dronda F, Gonzalez-Lopez A, Chaves F, Bravo R, Gutierrez M, et al. HIV-1 causing AIDS and death in a seronegative individual. Vox Sang 1994; 67:410–411. Cited Here | PubMed | CrossRef 23. Oka S, Ida S, Shioda T, Takebe Y, Kobayashi N, Shibuya Y, et al. Genetic analysis of HIV-1 during rapid progression to AIDS in an apparently healthy man. AIDS Res Hum Retroviruses 1994; 10:271–277. Cited Here | PubMed | CrossRef 24. Wegner S, Ohl C, DeNobile J, Mascola J, Carr J, Skillman D, et al. Case Report of a woman with seronegative HIV-1 infection [abstract #173]. AIDS Res Hum Retroviruses 1995; 11(Suppl 1):S107. Cited Here 25. Martin-Rico P, Pedersen C, Skinhoj P, Nielsen C, Lindhardt BO. Rapid development of AIDS in an HIV-1-antibody-negative homosexual man. AIDS 1995; 9:95–96. Cited Here | PubMed 26. Reimer L, Mottice S, Schable C, Sullivan P, Nakashima A, Rayfield M, et al. Absence of detectable antibody in a patient infected with human immunodeficiency virus. Clin Infect Dis 1997; 25:98–100. Cited Here | View Full Text | PubMed | CrossRef 27. Montagnier L, Brenner C, Chamaret S, Guetard D, Blanchard A, de Saint Martin J, et al. Human immunodeficiency virus infection and AIDS in a person with negative serology. J Infect Dis 1997; 175:955–959. Cited Here | View Full Text | PubMed | CrossRef 28. Michael NL, Brown AE, Voigt RF, Frankel SS, Mascola JR, Brothers KS, et al. Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection: evidence for highly susceptible human hosts. J Infect Dis 1997; 175:1352–1359. Cited Here | PubMed | CrossRef 29. Quinonez JM, Begue RE, Steele RW. HIV seronegativity in an infant with the acquired immunodeficiency syndrome. South Med J 1998; 91:879–881. Cited Here | View Full Text | PubMed 30. Sullivan PS, Schable C, Koch W, Do AN, Spira T, Lansky A, et al. Persistently negative HIV-1 antibody enzyme immunoassay screening results for patients with HIV-1 infection and AIDS: serologic, clinical, and virologic results. Seronegative AIDS Clinical Study Group. AIDS 1999; 13:89–96. Cited Here | View Full Text | PubMed | CrossRef 31. Rice PS, Cybulska B, Parry JV, Rowland-Jones S, Daniels RS. Reappearance of HIV antibody in an infected, seronegative individual after treatment with highly active antiretroviral therapy. AIDS 1999; 13:729–731. Cited Here | View Full Text | PubMed | CrossRef 32. Ellenberger DL, Sullivan PS, Dorn J, Schable C, Spira TJ, Folks TM, et al. Viral and immunologic examination of human immunodeficiency virus type 1-infected, persistently seronegative persons. J Infect Dis 1999; 180:1033–1042. Cited Here | View Full Text | PubMed | CrossRef 33. Candotti D, Adu-Sarkodie Y, Davies F, Baldrich-Rubio E, Stirrups K, Lee H, et al. AIDS in an HIV-seronegative Ghanaian woman with intersubtype A/G recombinant HIV-1 infection. J Med Virol 2000; 62:1–8. Cited Here | PubMed | CrossRef 34. De Rossi A, Giaquinto C, Del Mistro A, Zamarchi R, Chieco-Bianchi L. Onset of HIV-1 antibody production after highly active antiretroviral therapy in a seronegative HIV-1-infected child. AIDS 2000; 14:1284–1286. Cited Here | View Full Text | PubMed | CrossRef 35. Cardoso AR, Goncalves C, Pascoalinho D, Gil C, Ferreira AF, Bartolo I, et al. Seronegative infection and AIDS caused by an A2 subsubtype HIV-1. AIDS 2004; 18:1071–1074. Cited Here | View Full Text | PubMed | CrossRef 36. Monkemuller K, Fry LC, Decker JM, Rickes S, Smith PD. Severe gastrointestinal disease due to HIV-1-seronegative AIDS. Z Gastroenterol 2007; 45:706–709. Cited Here | PubMed | CrossRef 37. Chin BS, Lee SH, Kim GJ, Kee MK, Suh SD, Kim SS. Early identification of seronegative human immunodeficiency virus type 1 infection with severe presentation. J Clin Microbiol 2007; 45:1659–1662. Cited Here | PubMed | CrossRef 38. Novitsky V, Gaolathe T, Woldegabriel E, Makhema J, Essex M. A seronegative case of HIV-1 subtype C infection in Botswana. Clin Infect Dis 2007; 45:e68–e71. Cited Here | View Full Text | PubMed | CrossRef 39. Dalmau J, Puertas MC, Azuara M, Marino A, Frahm N, Mothe B, et al. Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection. Clin Infect Dis 2009; 48:229–238. Cited Here | View Full Text | PubMed | CrossRef 40. Bartolo I, Camacho R, Barroso H, Bezerra V, Taveira N. Rapid clinical progression to AIDS and death in a persistently seronegative HIV-1 infected heterosexual young man. AIDS 2009; 23:2359–2362. Cited Here | View Full Text | PubMed | CrossRef 41. Spivak AM, Brennan T, O'Connell K, Sydnor E, Williams TM, Siliciano RF, et al. A case of seronegative HIV-1 infection. J Infect Dis 2010; 201:341–345. Cited Here | View Full Text | PubMed | CrossRef 42. Jain MK, Skiest DJ, Cloud JW, Jain CL, Burns D, Berggren RE. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999–2000. Clin Infect Dis 2003; 36:1030–1038. Cited Here | View Full Text | PubMed | CrossRef 43. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103–6110. Cited Here | PubMed | CrossRef 44. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650–4655. Cited Here | PubMed | CrossRef 45. Mann DL, Murray C, Yarchoan R, Blattner WA, Goedert JJ. HLA antigen frequencies in HIV-1 seropositive disease-free individuals and patients with AIDS. J Acquir Immune Defic Syndr 1988; 1:13–17. Cited Here | View Full Text | PubMed 46. Itescu S, Mathur-Wagh U, Skovron ML, Brancato LJ, Marmor M, Zeleniuch-Jacquotte A, et al. HLA-B35 is associated with accelerated progression to AIDS. J Acquir Immune Defic Syndr 1992; 5:37–45. Cited Here | View Full Text | PubMed 47. Ngumbela KC, Day CL, Mncube Z, Nair K, Ramduth D, Thobakgale C, et al. Targeting of a CD8 T cell env epitope presented by HLA-B*5802 is associated with markers of HIV disease progression and lack of selection pressure. AIDS Res Hum Retroviruses 2008; 24:72–82. Cited Here | PubMed | CrossRef 48. Lazaryan A, Lobashevsky E, Mulenga J, Karita E, Allen S, Tang J, et al. Human leukocyte antigen B58 supertype and human immunodeficiency virus type 1 infection in native Africans. J Virol 2006; 80:6056–6060. Cited Here | PubMed | CrossRef 49. Bernardin F, Stramer SL, Rehermann B, Page-Shafer K, Cooper S, Bangsberg DR, et al. High levels of subgenomic HCV plasma RNA in immunosilent infections. Virology 2007; 365:446–456. Cited Here | PubMed | CrossRef 50. Gaufin T, Gautam R, Kasheta M, Ribeiro R, Ribka E, Barnes M, et al. Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain. Blood 2009; 113:4250–4261. Cited Here | PubMed | CrossRef 51. Gaufin T, Pattison M, Gautam R, Stoulig C, Dufour J, MacFarland J, et al. Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host. J Virol 2009; 83:10347–10357. Cited Here | PubMed | CrossRef 52. Bailey JR, Lassen KG, Yang HC, Quinn TC, Ray SC, Blankson JN, et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 2006; 80:4758–4770. Cited Here | PubMed | CrossRef 53. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009; 83:329–335. Cited Here | PubMed | CrossRef 54. Goulder PJ, Watkins DI. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 2008; 8:619–630. Cited Here | PubMed | CrossRef 55. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944–947. Cited Here | View Full Text | PubMed | CrossRef 56. Limou S, Le Clerc S, Coulonges C, Carpentier W, Dina C, Delaneau O, et al. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J Infect Dis 2009; 199:419–426. Cited Here | View Full Text | PubMed | CrossRef 57. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417:95–98.
@Ulqi https://academic.oup.com/ofid/article/3/1/ofv209/2460673 bu makalede şimdiye kadar en geç antikor pozitifliği olmuş hasta incelenmiş. Hasta hızla kötüye gitmiş. AİDS evresinde p24 pozitif gelmiş ama yine de antikorun pozitifleşmesi uzun süre almış. Bu makaleyi daha önce görmüştüm. Ama ilk paylaştığın makaleyi bu sitede ilk defa gördüm.
@pişmanpasif iyi de 25 hastanın 18'ne PCR yapılıyor da 7'sine gelince yok artık yapmayalım yorulduk mu deniliyor? Senin dediğine aklın alıyor mu gerçekten?
@Buson2 CDC DSÖ on milyonlarla Hiv pozitif hastasına göre mi çıakrım yapacaklar yoksa dünya tarihinde 1980'li yıllardan şimdiye kadar olan 7 vakaya göre mi? Eğer on milyonda bir vakalardan söz edilecekse neden tüm testlerin güvenirlikleri 100% olarak değil de yüzde 99,98 yada 99.99 oluyor? Neden 0.01 bile olsa yanılma payı bırakılıyor her zaman her şey yüzde yüz DSÖ yada CDC dediği gibi oluyorsa?
@Buson2 Böyle bir makale yoktu, git kime sorarsan sor. Üstüne üstlük hadi makale sahte diyelim ya o makalenin kullandığı kaynaklar da mı sahte? Makalenin güvenirliliği onun hikaye gibi olmaması, her cümlesine dayanak oluşturacak kaynak belirtmesidir. Bu yüzden buna makale deniliyor. Bu hikaye masal yada roman mı ki önüne gelen yazsın? Cahil cahil konuşuyorsunuz. Ayrıca makalenin yukarı kısmında kimlerin yazdığı belirtmiş. O isimleri araştırırsan kimlere ait olduğunu da görürsün. Cahile laf anlatmakla kendimi yeterince küçük düşürdüm zaten. Daha makalenin ne olduğunu bilmiyor gelmiş bana yalancı diyor.
@Buson2 Virüsü aldığı günü baz almasa ne olacak? Her Hiv bulaşı olan herkes öyle yada böyle antikor geliştirir. Bunun tek istisnası AİDS evresidir ki o zaman da p24 ortaya çıkar. Ama burada 7 hastada ne antikor ne p24 ne de PCR ortaya çıkmış. Sadece ve sadece cd4 sayısına göre HİV'den şüphenilmiş ve art tedavilerinden sonra bu hastalar normale dönülünce de emin olunmuş. Diğer soruna da gelince yukarıda yazdım ya çevirirken, hayır bağışıklığı baskılayan hiçbir hastalıkları yokmuş. Ve bunu şu cümleyle birebir olarak belirtmiş. '' Ayrıca tanımlanan hastaların hiçbirinde, onları zayıflamış bir bağışıklık tepkisine yatkın hale getirecek tıbbi bir durum yoktu.'' Hatta Tabloyla da göstermiş.
@Buson2 Ama onların sunduğu makalelerin hiçbirinde bırak antikor yanıtını p24 antijen yada PCR yanıtı almamış hiçbir hasta yoktu. Burada uzun süredir olduğumdan biliyorum. Dilersen buradaki arşii de taraya bilirsin. Daha önce değil Akif yada diğerleri hiç kimse böyle bir makale sunmamıştı. İyi paranoyak olup çıktınız sizde